Search

Your search keyword '"Posthuma, Ward"' showing total 15 results
Start Over Author "Posthuma, Ward" Publication Year Range Last 10 years
15 results on '"Posthuma, Ward"'

1. Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Author

Saberi Hosnijeh, Fatemeh, van der Straten, Lina, Kater, Arnon P., van Oers, Marinus H.J., Posthuma, Ward F.M., Chamuleau, Martine E.D., Bellido, Mar, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, de Boer, Fransien, te Raa, G. Doreen, Kerst, J. Martijn, Marijt, Erik W.A., Raymakers, Reinier A.P., Koene, Harry R., Schaafsma, Martijn R., Dobber, Johan A., Tonino, Sanne H., Kersting, Sabina S., Langerak, Anton W., and Levin, Mark-David

Published
2020
Full Text
View/download PDF

3. Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Author

De Groen, Ruben A.L., primary, De Groot, Fleur A, additional, De Haan, Lorraine M., additional, van Wezel, Tom, additional, Noordenbos, Troy, additional, Boehringer, Stefan, additional, Van Eijk, Ronald, additional, Raghoo, Richard, additional, Ruano, Dina, additional, Sijs-Szabo, Aniko, additional, te Boome, Liane, additional, Terpstra, Valeska, additional, Levenga, Henriette, additional, Nicolae, Aline, additional, Posthuma, Ward, additional, Focke-Snieders, Isabelle, additional, Hardi, Lizan, additional, den Hartog, Wietske, additional, Böhmer, Lara H., additional, Van Den Berg, Anke, additional, Mutseaers, Pim, additional, Van Der Poel, Marjolein W.M., additional, Abdul Hamid, Myrurgia, additional, Woei-a-Jin, F.J. Sherida H., additional, Janssens, Ann, additional, Tousseyn, Thomas, additional, Bovée, Judith, additional, Veelken, Hendrik, additional, Pals, Steven T, additional, Diepstra, Arjan, additional, Nijland, Marcel, additional, Kersten, Marie José, additional, Jansen, Patty M., additional, Cleven, Arjen, additional, and Vermaat, Joost S.P., additional

Published
2022
Full Text
View/download PDF

4. P080: The BETER-REFLECT Biobank: a REsource For studies on Late Effects of Cancer Treatment

Author

Mieras, Adinda, primary, Nijdam, Annelies, additional, Aleman, Berthe M. P., additional, Daniels, Laurien, additional, De Jongh, Eva, additional, Janus, Cécile P.M., additional, Krol, Stijn, additional, Ta, Bastiaan D.P., additional, Ong, Francisca, additional, Van Spronsen, Dick Johan, additional, Posthuma, Ward, additional, Plattel, Wouter J., additional, Oostvogels, Rimke, additional, Verschueren, Karijn, additional, Zijlstra, Josée. M., additional, and Van Leeuwen, Flora E., additional

Published
2022
Full Text
View/download PDF

5. Integration of Mutational Signature Analysis with 3D Chromatin Data Unveils Differential AID-Related Mutagenesis in Indolent Lymphomas

Author

Sepulveda-Yanez, Julieta H., primary, Alvarez-Saravia, Diego, additional, Fernandez-Goycoolea, Jose, additional, Aldridge, Jacqueline, additional, van Bergen, Cornelis A. M., additional, Posthuma, Ward, additional, Uribe-Paredes, Roberto, additional, Veelken, Hendrik, additional, and Navarrete, Marcelo A., additional

Published
2021
Full Text
View/download PDF

6. High Frequencies of Mutated EZH2 and IRF8 and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype

Author

De Groen, Ruben A.L., primary, Van Eijk, Ronald, additional, van Wezel, Tom, additional, Raghoo, Richard, additional, Schrader, Anne-Roos, additional, Jansen, Patty M., additional, briaire-De Bruijn, Inge, additional, Kleiverda, Karin, additional, Vlasveld, Tom, additional, Terpstra, Valeska, additional, Levenga, Henriette, additional, Nicolae, Aline, additional, Posthuma, Ward, additional, Focke-Snieders, Isabelle, additional, Hardi, Lizan, additional, den Hartog, Wietske, additional, Van Den Berg, Anke, additional, Diepstra, Arjan, additional, Lugtenburg, Pieternella, additional, Kersten, Marie José, additional, Pals, Steven T, additional, Veelken, Hendrik, additional, Bovée, Judith, additional, Cleven, Arjen, additional, and Vermaat, Joost, additional

Published
2019
Full Text
View/download PDF

7. Feasibility and efficacy of addition of individualized dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author

Kater, Arnon P, van Oers, Marinus H J, van Norden, Yvette, van der Straten, Lina, Driessen, Julia, Posthuma, Ward F M, Schipperus, Martinus, Chamuleau, Martine E D, Nijland, Marcel, Doorduijn, Jeanette K, Van Gelder, Michel, Hoogendoorn, Mels, De Croon, Francien, Wittebol, Shulamiet, Kerst, J Martijn, Marijt, Erik W A, Raymakers, Reinier A P, Schaafsma, Martijn R, Dobber, Johan A, Kersting, Sabina A, Levin, Mark-David, and HOVON CLL study group

Subjects
Hematology
Abstract

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m 2 daily), rituximab (375 mg/m 2 cycle 1 and 500 mg/m 2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2-and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34.

Published
2019

9. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia

Author

Kater, Arnon P., primary, van Oers, Marinus H.J., additional, van Norden, Yvette, additional, van der Straten, Lina, additional, Driessen, Julia, additional, Posthuma, Ward F.M., additional, Schipperus, Martin, additional, Chamuleau, Martine E.D., additional, Nijland, Marcel, additional, Doorduijn, Jeanette K., additional, Van Gelder, Michel, additional, Hoogendoorn, Mels, additional, De Croon, Francien, additional, Wittebol, Shulamiet, additional, Kerst, J. Martijn, additional, Marijt, Erik W.A., additional, Raymakers, Reinier A.P., additional, Schaafsma, Martijn R., additional, Dobber, Johan A., additional, Kersting, Sabina, additional, and Levin, Mark-David, additional

Published
2018
Full Text
View/download PDF

10. The BETER survivorship care initiative for Hodgkin lymphoma; Tailored survivorship care for late effects of treatment

Author

Dekker, Nicky, Van'T Veer, Mars B., Aleman, Berthe M.P., Van Leeuwen, Flora E., Raemaekers, John M.M., Schaapveld, Michael, Opstal-Van Winden, Annemieke, De Boer, Jan Paul, Sombroek, Cherita, Poortmans, Philip, Van Der Maazen, Richard, Lugtenburg, P. J.Elly, Janus, Cecile, Noordijk, Ed, Krol, A. D.G.Stijn, Daniels, Laurien, Zijlstra, Josée, Meijer, Otto, Petersen, Eefke, Buter, Denise, De Weijer, Roel, Roesink, Judith, Kluin-Nelemans, J. C.Hanneke, Van Imhoff, Gustaaf, De Vries, Floriske, Beijert, Max, Kersten, Marie José, Oldenburger, Foppe, Dieleman, Edith, Schouten, Harry, Borger, Jacques, Van De Voorde, Lien, Verschueren, Karijn, Schippers, Maaike, Verbeeten, Bernard, Ong, Francisca, Dorresteijn, Lucille, Schimmel, Erik, Bouma, Paul, Muller, Karin, Lybeert, Marnix, Dompeling, Ellen, Manenschijn, Annelies, Vos-Westerman, J. Hanneke, Van Kampen, Daphne, Dielwart, Michel, Posthuma, Ward, Böhmer, Lara, Te Boome, Liane, Visser, Hein, Epidemiology and Data Science, EMGO - Quality of care, Hematology, CCA - Imaging and biomarkers, CCA - Disease profiling, CCA - Imaging, Radiation Oncology, VU University medical center, and Oral and Maxillofacial Surgery / Oral Pathology

Subjects
humanities
Abstract

The Dutch BETER consortium has established a national care infrastructure for Hodgkin lymphoma survivors. 'BETER' [the Dutch word for 'better'] stands for Better care after Hodgkin lymphoma (HL): Evaluation of longterm Treatment Effects and screening Recommendations. The survivorship care focuses on longterm effects of HL treatment. Over 10,000 HL survivors who were treated in the period spanning 19652008 have been identified. As part of the survivorship care initiative, specific BETER outpatient clinics have been set up. A dedicated website, www.beternahodgkin.nl, provides HL survivors with relevant information. The stakeholders of the BETER survivorship care programme aim to achieve an improved healthy life expectancy for patients treated for HL.

Published
2016

12. High Frequencies of Mutated EZH2and IRF8and Other Epigenetic Genes in Primary Bone Lymphomas Are Indicative of GCB-Phenotype

Author

De Groen, Ruben A.L., Van Eijk, Ronald, van Wezel, Tom, Raghoo, Richard, Schrader, Anne-Roos, Jansen, Patty M., briaire-De Bruijn, Inge, Kleiverda, Karin, Vlasveld, Tom, Terpstra, Valeska, Levenga, Henriette, Nicolae, Aline, Posthuma, Ward, Focke-Snieders, Isabelle, Hardi, Lizan, den Hartog, Wietske, Van Den Berg, Anke, Diepstra, Arjan, Lugtenburg, Pieternella, Kersten, Marie José, Pals, Steven T, Veelken, Hendrik, Bovée, Judith, Cleven, Arjen, and Vermaat, Joost

Abstract

Introduction

Published
2019
Full Text
View/download PDF

13. Efficacy and Safety of First-Line Therapy with Chlorambucil, Rituximab and Individualized Dose Lenalidomide in FCR-Unfit Patients with Advanced Chronic Lymphocytic Leukemia (CLL): A Phase I/II HOVON Trial

Author

Kater, Arnon P., Van Oers, Marinus H.J. H.J., Norden, Yvette, Liu, Roberto D., Schipperus, Martin R., Chamuleau, Martine, Nijland, Marcel, Doorduijn, Jeanette K., van Gelder, Michel, Hoogendoorn, Mels, Croon-de Boer, Fransien, Wittebol, Shulamit, Kerst, Martijn, Marijt, Willem, Posthuma, Ward, Raymakers, Reinier, Schaafsma, Ron, Dobber, Johan, Kersting, Sabina, and Levin, Mark-David

Abstract

Introduction.Since publication of the pivotal CLL011 phase 3 trial, combination of chlorambucil and anti-CD20 MAb has become the standard first-line CLL treatment for patients unfit for FCR. Lenalidomide (Len) has been proven effective both as monotherapy and in combination with rituximab. Although recent studies in CLL suggest that Len is mostly beneficial as consolidation treatment, the exact place and duration of this drug is still not optimized. Moreover, Len has shown a distinct and more difficult to manage toxicity profile in the context of CLL, potentially hampering combination treatment with this drug. We therefore conducted a phase 2 study to evaluate efficacy and safety of a combination of chlorambucil, rituximab and individual dosed Len (induction-I) followed by 6 months of Len monotherapy (induction-II).

Published
2017
Full Text
View/download PDF

15. Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Author

Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, and Levin MD

Subjects
Adolescent, Adult, Chlorambucil administration & dosage, Disease-Free Survival, Feasibility Studies, Female, Humans, Lenalidomide administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell metabolism, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Male, Middle Aged, Rituximab administration & dosage, Survival Rate, Vidarabine administration & dosage, Vidarabine analogs & derivatives, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Leukemia, Lymphocytic, Chronic, B-Cell mortality
Abstract

Lenalidomide has been proven to be effective but with a distinct and difficult to manage toxicity profile in the context of chronic lymphocytic leukemia, potentially hampering combination treatment with this drug. We conducted a phase 1-2 study to evaluate the efficacy and safety of six cycles of chlorambucil (7 mg/m 2 daily), rituximab (375 mg/m 2 cycle 1 and 500 mg/m 2 cycles 2-6) and individually-dosed lenalidomide (escalated from 2.5 mg to 10 mg) (induction-I) in first-line treatment of patients with chronic lymphocytic leukemia unfit for treatment with fludarabine, cyclophosphamide and rituximab. This was followed by 6 months of 10 mg lenalidomide monotherapy (induction-II). Of 53 evaluable patients in phase 2 of the study, 47 (89%) completed induction-I and 36 (68%) completed induction-II. In an intention-to-treat analysis, the overall response rate was 83%. The median progression-free survival was 49 months, after a median follow-up time of 27 months. The 2- and 3-year progression-free survival rates were 58% and 54%, respectively. The corresponding rates for overall survival were 98% and 95%. No tumor lysis syndrome was observed, while tumor flair reaction occurred in five patients (9%, 1 grade 3). The most common hematologic toxicity was grade 3-4 neutropenia, which occurred in 73% of the patients. In conclusion, addition of lenalidomide to a chemotherapy backbone followed by a fixed duration of lenalidomide monotherapy resulted in high remission rates and progression-free survival rates, which seem comparable to those observed with novel drug combinations including novel CD20 monoclonal antibodies or kinase inhibitors. Although lenalidomide-specific toxicity remains a concern, an individualized dose-escalation schedule is feasible and results in an acceptable toxicity profile. EuraCT number: 2010-022294-34 ., (Copyright© 2019 Ferrata Storti Foundation.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results